NASDAQ:CTMX - CytomX Therapeutics, Inc.
$9.99
 $-0.13
-1.28%
4:00PM EDT
2019-04-18
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CTMX     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 22   199. 07   233. 87  
42 stocks rank:  4. 17 K 1. 43 K 1. 06 K
# analyst opinions:  10. 00   14. 48   14. 09  
mean recommendation:  1. 80   2. 09   2. 01  

quick ratio:  4. 46   5. 29   1. 92  
current ratio:  4. 55   5. 64   2. 40  

target price low:  14. 01   84. 50   115. 74  
target price avg:  16. 00   110. 73   137. 39  
target price high:  25. 20   136. 41   157. 80  
1-yr high:  27. 01   114. 11   138. 85  
last close:  9. 99   87. 56   116. 78  
50-day avg:  12. 59   95. 43   123. 53  
200-day avg:  16. 99   94. 13   121. 20  
1-yr low:  9. 50   72. 67   98. 41  
volume:  189. 08 K 2. 43 M 4. 85 M
50-day avg volume:  606. 99 K 2. 72 M 4. 97 M
200-day avg volume:  449. 85 K 2. 90 M 4. 58 M

1-day return:  -1. 28 % -0. 40 % 0. 07 %
this week return:  -7. 07 % -5. 72 % -4. 11 %
12-wk return:  -40. 71 % 1. 78 % -0. 04 %
52-wk return:  -60. 43 % 10. 81 % 14. 09 %

enterprise value (EV):  48. 82 M 51. 19 B 117. 96 B
market cap:  450. 65 M 43. 00 B 104. 52 B
EBITDA:  -75. 99 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -0. 64   4. 34   13. 27  
enterprise/revenue (EV/R):  0. 82   68. 16   13. 68  
total revenue:  59. 50 M 10. 61 B 38. 24 B
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -84. 60 M 2. 20 B 4. 21 B

shares outstanding:  45. 11 M 570. 91 M 1. 24 B
shares:  41. 16 M 571. 02 M 1. 23 B
shares short:  1. 90 M 9. 93 M 16. 79 M
shares short prior month:  2. 44 M 9. 96 M 16. 58 M
short ratio:  1. 94   5. 31   3. 30  
short % of float:  5. 86 % 5. 81 % 2. 61 %
total cash/share:  9. 67   11. 13   9. 30  
total cash:  436. 13 M 6. 70 B 7. 10 B
free cash flow:  8. 21 M 3. 58 B 4. 74 B
operating cash flow:  -75. 52 M 4. 14 B 6. 32 B

book value:  2. 90   12. 76   26. 84  
price/book:  3. 44   3. 08   -1. 74  
gross profits:  59. 50 M 8. 03 B 34. 77 B
operating margins:  -130. 88 % -721. 97 % -88. 82 %
EBITDA margins:  -127. 71 % 10. 94 % 22. 54 %
profit margins:  -142. 19 % 7. 81 % 10. 60 %
gross margins:  100. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  -31. 47 % --- ---
1-yr mean volatility:  -0. 30 % 0. 03 % 0. 04 %

1-yr EPS:  -2. 03   2. 39   4. 08  
forward EPS:  -2. 71   3. 97   7. 14  
P/E:  -4. 92   13. 59   22. 83  
forward P/E:  -3. 97   -20. 05   14. 49  
PE/G:  0. 09   -1. 46   1. 68  
growth:  -57. 60 % 126. 81 % 29. 29 %
earnings high:  -0. 41   1. 02   1. 63  
earnings avg:  -0. 52   0. 76   1. 51  
earnings low:  -0. 70   0. 47   1. 39  
revenue high:  18. 50 M 2. 68 B 10. 71 B
revenue avg:  12. 87 M 2. 59 B 10. 49 B
revenue low:  6. 25 M 2. 49 B 10. 25 B
return on assets:  -11. 39 % -2. 80 % 5. 29 %
return on equity:  -84. 28 % -18. 52 % 7. 38 %
revenue growth:  -57. 60 % 92. 55 % 19. 15 %
revenue/share:  1. 43   13. 27   55. 24  

beta (1yr vs S&P500):  1. 96   1. 24   0. 93  
sharpe (1yr):  -1. 10   0. 29   0. 60  

held % insiders:  2. 50 % 6. 38 % 3. 38 %
held % institutions:  86. 29 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : CTMX
.     + 1.13 =          1.13 :: INITIAL WEIGHT
.   + 65.783 =        66.913 :: inverse volume-to-price addition
.   + 41.513 =       108.426 :: spline projection addition
.    x 3.568 =       386.886 :: 13 weeks' performance factor
.    x 0.607 =       234.892 :: one-year gains+dividend factor
.    x 1.432 =       336.371 :: industry recommendation factor
.    x 2.591 =       871.681 :: symbol recommendation factor
.    x 1.012 =       882.167 :: EV/R factor
.    x 0.999 =       881.162 :: return on assets factor
.    x 0.992 =       873.736 :: return on equity factor
.    x 0.994 =       868.703 :: revenue growth factor
.    x 2.807 =      2438.411 :: current ratio factor
.    x 1.136 =      2768.897 :: quick ratio factor
.    x 1.231 =      3408.628 :: short ratio factor
.    x 2.034 =      6934.556 :: price-to-book factor
.    x 2.089 =      14484.08 :: P/E weight
.     x 1.85 =     26793.697 :: PE/G factor
.    x 1.328 =     35586.595 :: beta factor
.    x 0.823 =     29278.591 :: sharpe factor
.    x 1.673 =     48990.908 :: target low factor
.    x 1.259 =     61657.178 :: target mean factor
.    x 1.123 =      69265.09 :: target high factor
.    x 1.312 =     90851.444 :: industry 2-weeks return factor
.    x 0.936 =     85027.072 :: "drift" penalty 4 days ago
.    x 0.997 =     84756.845 :: overall "drift" factor
.    x 0.999 =     84645.702 :: largest single-day jump factor
.    x 0.139 =     11772.698 :: low price factor
.      x 1.0 =     11770.801 :: factor hist industry gain for week 15
.   cubeRoot =        22.748 :: reduced to standardize
.   - 22.931 =          0.22 :: add/subtract for performance
.                       0.22 :: FINAL WEIGHT for NASDAQ:CTMX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org